High-Resolution Liquid Biopsy Using Nanopore Sequencing for Longitudinal Tracking of Minimal Residual Disease in Acute Myeloid Leukemia
Keywords:
AML, Minimal Residual Disease, Liquid Biopsy, Nanopore Sequencing, cfDNA, Longitudinal Surveillance, Precision OncologyAbstract
Monitoring minimal residual disease (MRD) in Acute Myeloid Leukemia (AML) remains a major challenge in post-treatment surveillance. Conventional MRD detection techniques lack sensitivity and scalability for longitudinal analysis. This study presents a novel approach leveraging Nanopore sequencing on cell-free DNA (cfDNA) from plasma (liquid biopsy) to sensitively detect AML-specific mutations with high resolution over time. A panel targeting common AML mutations was employed, and serial samples were taken from 20 patients across 18 months. Nanopore sequencing enabled real-time mutation calling and lineage tracing, highlighting its potential as a non-invasive tool for precision monitoring of MRD.
References
Ivey, A., et al. (2016). Assessment of minimal residual disease in NPM1-mutated AML. New England Journal of Medicine, 374(5), 422–433.
Freeman, S.D., et al. (2012). Measurable residual disease in AML: Flow cytometry vs molecular methods. Blood, 120(15), 2987–2996.
Hourigan, C.S., & Karp, J.E. (2013). Minimal residual disease in AML. Nature Reviews Clinical Oncology, 10(8), 460–471.
Jongen-Lavrencic, M., et al. (2018). Molecular minimal residual disease in AML. New England Journal of Medicine, 378(13), 1189–1199.
Thol, F., et al. (2012). Clinical implications of Sanger-based detection in AML. Leukemia, 26(5), 1126–1132.
Oxnard, G.R., et al. (2014). Noninvasive detection of resistance mutations via cfDNA. Clinical Cancer Research, 20(6), 1698–1705.
Murtaza, M., et al. (2013). Non-invasive analysis of tumor evolution. Nature, 497(7447), 108–112.
Wan, J.C.M., et al. (2017). Liquid biopsies come of age: towards implementation. Nature Reviews Cancer, 17(4), 223–238.
Sanchez, D., et al. (2017). Targeted sequencing of plasma DNA for MRD. Blood Advances, 1(12), 875–882.
Chabon, J.J., et al. (2016). Integrating cfDNA with cancer tracking. Nature Genetics, 48(10), 1156–1162.
Downloads
Published
Issue
Section
License
Copyright (c) -1 Lachlan Chris (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
